the AFFIRM Investigators* Background-Expectations that reestablishing and maintaining sinus rhythm in patients with atrial fibrillation might improve survival were disproved in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. This report describes the cause-specific modes of death in the AFFIRM treatment groups. Methods and Results-All deaths in patients enrolled in AFFIRM underwent blinded review by the AFFIRM Events Committee, and a mode of death was assigned. In AFFIRM, 2033 patients were randomized to a rhythm-control strategy and 2027 patients to a rate-control strategy. During a mean follow-up of 3.5 years, there were 356 deaths in the rhythm-control patients and 310 deaths in the rate-control patients (Pϭ0.07). In the rhythm-control group, 129 patients (9%) died of a cardiac cause, and in the rate-control group, 130 patients (10%) died (Pϭ0.95). Both groups had similar rates of arrhythmic and nonarrhythmic cardiac deaths. The numbers of vascular deaths were similar in the 2 groups: 35 (3%) in the rhythm-control group and 37 (3%) in the rate-control group (Pϭ0.82). There were no differences in the rates of ischemic stroke and central nervous system hemorrhage. In the rhythm-control group, there were 169 noncardiovascular deaths (47.5% of the total number of deaths), whereas in the rate-control arm, there were 113 noncardiovascular deaths (36.5% of the total number of deaths) (Pϭ0.0008). Differences in noncardiovascular death rates were due to pulmonary and cancer-related deaths. Conclusions-Management of atrial fibrillation with a rhythm-control strategy conferred no advantage over a rate-control strategy in cardiac or vascular mortality and may be associated with an increased noncardiovascular death rate.

Recent reports suggest that anabolic steroid use might deleteriously affect left ventricular function. To examine this possibility, the present study measured left ventricular size and function with use of Doppler echocardiographic techniques in 23 weight lifters: 12 who were currently using anabolic steroids and 11 who reported that they had never used these drugs. Drug users had administered anabolic steroids to themselves for at least three cycles over the past year. All studies were interpreted by blind review and group assignment was confirmed by urine testing. Average age, years of exercise training and body weight, as well as heart rate and blood pressure at rest were similar in both groups. Cardiac dimensions (mean +/- SD) including left ventricular diastolic cavity diameter (57 +/- 3 vs. 56 +/- 5 mm), septal thickness (10 +/- 2 vs. 9 +/- 1 mm), posterior wall thickness (8 +/- 1 vs. 8 +/- 1 mm) and myocardial mass (149 +/- 27 vs. 135 +/- 21 g) did not differ between the anabolic steroid users and nonusers, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)

Stress echocardiography is a useful noninvasive modality for measuring dynamic outflow gradient and contractility changes in patients with hypertrophic cardiomyopathy (HCM) or dilated cardiomyopathy (DCM). In patients with HCM, stress echocardiography may determine the degree of outflow tract obstruction at rest and with activity, can detect occult systolic dysfunction in symptomatic patients with a normal resting left ventricular ejection fraction, and can also be utilized to monitor the efficacy of treatment. In individuals suffering from DCM, stress echocardiography is an important aid in the evaluation of the etiology, diagnosis, and prognosis of the disease as well as the functional status of the patient during either exercise or simulated stress conditions. Dobutamine stress echocardiography, by providing a measurement of the myocardial reserve, is a useful tool to predict the systolic recovery and clinical outcome of patients with heart failure. The stress-induced change in the wall motion score index can also be used as an accurate alternative to predict the peak oxygen consumption rate and exercise capacity of the same patient population. Finally, stress echocardiography has also been used in the identification of the predilated phase of cardiomyopathy in individuals with high clinical suspicion of the disease.